His primary areas of study are Cell biology, Molecular biology, Transcription factor, Transcription and c-jun. The various areas that Peter Angel examines in his Cell biology study include Endocrinology, Cellular differentiation, JUNB, Osteoblast and Internal medicine. His Molecular biology research incorporates themes from Amino acid, Complementary DNA, Gene, Promoter and Kinase.
Peter Angel has included themes like Regulation of gene expression, Glucocorticoid receptor, Binding site and Cancer research in his Transcription factor study. His Regulation of gene expression research includes themes of Sequence homology, Base sequence, AP-1 Complex, Bioinformatics and Neoplastic transformation. His works in Transactivation and Enhancer RNAs are all subjects of inquiry into Transcription.
Cell biology, Cancer research, Molecular biology, Transcription factor and JUNB are his primary areas of study. His study in Cell biology is interdisciplinary in nature, drawing from both Endocrinology, Internal medicine, Keratinocyte and Cellular differentiation. His work deals with themes such as Carcinogenesis, Inflammation, Immunology and Podoplanin, which intersect with Cancer research.
His work focuses on many connections between Inflammation and other disciplines, such as Immune system, that overlap with his field of interest in Cancer. His work carried out in the field of Molecular biology brings together such families of science as Regulation of gene expression, Transcription, Gene expression, Gene and c-jun. His Transcription factor research integrates issues from Promoter, Activator and Binding site.
Peter Angel spends much of his time researching Cancer research, Glioma, Cell biology, In vivo and Podoplanin. He combines subjects such as Cancer, Progenitor cell, JUNB, Downregulation and upregulation and Fibrosis with his study of Cancer research. His study explores the link between Cancer and topics such as Immune system that cross with problems in Inflammation.
His study with JUNB involves better knowledge in Transcription factor. His Glioma research also works with subjects such as
Peter Angel mostly deals with Cancer research, Cell biology, Glioma, Carcinogenesis and Fibroblast. His Cancer research research is multidisciplinary, relying on both In vitro, Downregulation and upregulation, Metabolomics and Brain tumor, Pathology. His work in the fields of Signal transduction overlaps with other areas such as Context.
His Glioma research is multidisciplinary, incorporating perspectives in Chemotherapy, Cancer stem cell, Slice preparation, Gentamicin protection assay and Neural stem cell. The Carcinogenesis study combines topics in areas such as Calgranulin, Senescence, S100A8 and S100A9. Peter Angel works mostly in the field of Fibroblast, limiting it down to topics relating to Wound healing and, in certain cases, Extracellular matrix, Reprogramming, Transcription factor and Chromatin immunoprecipitation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.
Peter Angel;Michael Karin.
Biochimica et Biophysica Acta (1991)
AP-1 subunits: quarrel and harmony among siblings
Jochen Hess;Peter Angel;Marina Schorpp-Kistner.
Journal of Cell Science (2004)
DNA binding of the glucocorticoid receptor is not essential for survival
Holger M Reichardt;Klaus H Kaestner;Jan Tuckermann;Oliver Kretz.
Cell (1998)
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region.
Peter Angel;I. Baumann;B. Stein;H. Delius.
Molecular and Cellular Biology (1987)
Prolonged activation of jun and collagenase genes by tumour necrosis factor- α
David A. Brenner;Maureen O'Hara;Peter Angel;Mario Chojkier.
Nature (1989)
Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun.
Robert Chiu;Peter Angel;Michael Karin.
Cell (1989)
ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents.
H. Van Dam;D. Wilhelm;I. Herr;A. Steffen.
The EMBO Journal (1995)
Control of cell cycle progression by c-Jun is p53 dependent
Martin Schreiber;Andrea Kolbus;Fabrice Piu;Fabrice Piu;Axel Szabowski.
Genes & Development (1999)
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice
Dominique Stickens;Danielle J. Behonick;Nathalie Ortega;Babette Heyer.
Development (2004)
S100A8 and S100A9 in inflammation and cancer.
Christoffer Gebhardt;Julia Németh;Peter Angel;Jochen Hess.
Biochemical Pharmacology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Charité - University Medicine Berlin
Medical University of Vienna
German Cancer Research Center
Leibniz Association
University Hospital Heidelberg
University of Melbourne
German Cancer Research Center
Heidelberg University
German Cancer Research Center
University of California, San Diego
Fujikura (Japan)
Johnson & Johnson (United States)
Heinrich Heine University Düsseldorf
Queen's University
University of Zurich
University of Padua
Washington University in St. Louis
University of Technology Malaysia
National Center for Atmospheric Research
University of Jyväskylä
University of Strathclyde
Brigham and Women's Hospital
State University of New York
Collège de France
University of Wisconsin–Madison
Zoo Miami